Health Catalyst

HCAT

Market cap $95.3M

Health Catalyst, Inc. (HCAT) Q1 2026 Earnings Call Transcript

Health Catalyst NASDAQ: HCAT reported first-quarter 2026 results that topped its own expectations, while management outlined a broad restructuring plan aimed at simplifying the company's operating model, reducing costs and shifting the business further toward technology-led growth.

Health Catalyst (HCAT) came out with quarterly earnings of $0.02 per share, beating the Zacks Consensus Estimate of $0.01 per share. This compares to earnings of $0.01 per share a year ago.

While the top- and bottom-line numbers for Health Catalyst (HCAT) give a sense of how the business performed in the quarter ended March 2026, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

SALT LAKE CITY, May 11, 2026 (GLOBE NEWSWIRE) -- Health Catalyst, Inc. (“Health Catalyst,” Nasdaq: HCAT), a healthcare intelligence company designed to accelerate measurable improvement for health systems, today reported financial results for the quarter ended March 31, 2026. “We delivered solid first quarter results, with revenue and adjusted EBITDA exceeding expectations,” said Ben Albert, Chief Executive Officer of Health Catalyst.

Evaluate the expected performance of Health Catalyst (HCAT) for the quarter ended March 2026, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metrics for better insight.

SALT LAKE CITY, May 01, 2026 (GLOBE NEWSWIRE) -- Health Catalyst, Inc. ("Health Catalyst", Nasdaq: HCAT), a healthcare intelligence company designed to accelerate measurable improvement for health systems, will release its first quarter 2026 operating results on Monday, May 11, 2026, after market close. In conjunction, the company will host a conference call to review the results at 5:00 pm ET on the same day.

SALT LAKE CITY, April 30, 2026 (GLOBE NEWSWIRE) -- Health Catalyst, Inc. (“Health Catalyst”, Nasdaq: HCAT), a healthcare intelligence company designed to accelerate measurable improvement for health systems, today announced that Steve Nelson, Executive Vice President and President of Aetna, a CVS Health company, has been appointed to its Board of Directors, effective May 1, 2026.  Nelson's appointment follows the naming of Ben Albert as CEO and Justin Spencer as Chairman of the Board earlier this year, continuing a deliberate pattern of leadership moves designed to accelerate the company's transformation– executing on a single, coordinated strategy to help health systems address cost, clinical outcomes, and consumer experience as one imperative.

Although the revenue and EPS for Health Catalyst (HCAT) give a sense of how its business performed in the quarter ended December 2025, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

Health Catalyst (HCAT) came out with quarterly earnings of $0.08 per share, missing the Zacks Consensus Estimate of $0.09 per share. This compares to earnings of $0.04 per share a year ago.